Crisis in science is turning Nobel laureates into fighters for scientific revolution
Global news media as well as prominent scientists are highlighting the crisis in both physics and cosmology, and predicting a major scientific revolution.
This week, an article appeared in The Atlantic magazine [titled 'The Nobel Prize winner who thinks we have the universe all wrong']. It featured Adam Riess, who won a Nobel Prize for the shocking discovery that the expansion of universe is accelerating, due to Dark Energy. But now he thinks that the theory must be wrong. The article warned about scientists talking of revolution. A growing number now say that the 'standard model of cosmology' should be replaced. Adam Riess is among them. Way back in 2013, in a conversation with WIRED, David Gross, a Nobel laureate in physics, warned about the crisis in physics and advocated a revolution. ['Nobel laureate says physics is in need of a revolution'; WIRED; Peter Byrne].
An article in NewScientist (Dan Hooper) was titled 'The four puzzles that tell us a cosmological revolution is coming'. Another article in Live Science (Kelly Dickerson) was titled 'Why a Physics Revolution Might Be on Its Way: Physics may be turned on its head soon'. Global newspapers (BBC News, The New York Times, The Guardian, Forbes, et al) are raising alarm over the crisis in both physics and cosmology. Actually, science is in crisis, because nature does not draw clear lines between biology, chemistry, physics, math, and cosmology. Such demarcations are human-made, and artificial. After all, biology is based on chemistry, which in turn is based on physics. Global news media as well as prominent scientists are predicting that a BIG scientific revolution is imminent.
A scientific revolution is INEVITABLE because of four strong reasons:
1) All three conditions are satisfied. The three key steps to overthrow and replace any accepted scientific theory are: a) Reproduce the successes of the presently accepted theory. b) Explain what it cannot. c) Make new predictions that differ and can be tested.
2) Physics and cosmology are both in crisis due to wrong notion about the shape, size and workings of the universe. The universe is actually like a (hyper) balloon, and is expanding.
3) Science rests on faulty Math. Luckily, the mistakes are so easy to comprehend that even the common people can easily understand what is wrong. A baker can understand, and so can butchers or cobblers.
4) Einstein was wrong. His concept of four dimensional SpaceTime continuum is the biggest mistake in science. Time itself is NOT the fourth dimension; time emerges from motion along 4th space dimension.
Every scientific revolution in the past has ended up having enormous social and cultural influence. For example, Copernicus's helio-centrism threatened human sense of being right in the center of the universe (and hence the 'sun centric model' was bitterly opposed by the powerful church but ultimately all oppositions proved futile. In fact, the church had to issue a public apology recently for its role). Darwin's theory of evolution challenged the intuition that humans were fundamentally different from other animals. People during that time were outraged and dismissed it as plain nonsense. Yet, yesterday's nonsense ended up as today's commonsense! Einstein's relativity upended all faith in common sense ideas about the flow of time. Time started mixing with space for very fast moving objects, and time revealed its character as another dimension!
The upcoming scientific revolution shall be the greatest ever, and force humans to change the way of thinking about the most basic features of the universe, including the nature of space and time. Space and Time underlies Physics and Cosmology, and are the most fundamental concepts imaginable in entire Science. It will be a conceptual revolution that would have implications far beyond the world of science. The scale of social and cultural impact of the upcoming scientific revolution is quite unthinkable.
A scientific revolution is unstoppable. No one can stop a revolution whose time has come.
[194 National Anthems tunes have been merged into a single tune using World's most intelligent, musical A.I. software 'Emmy', to create this United Nations Anthem (World Anthem). Kindly watch and share: https://www.youtube.com/watch?v=0SHycxT5-oM ]
Mr. Joseph T. Kurien (a former Cochin University graduate) is an independent researcher and a part-time science writer. He presently works in Manappuram software and consultancy.
Media Contact
Company Name: Manappuram software and consultancy
Contact Person: Joseph T. Kurien
Email: Send Email
State: Kerala
Country: India
Website: https://www.facebook.com/profile.php?id=61559986357449
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
2 hours ago
- CTV News
U.S. reports another arrest of Chinese scientist with no permit to send biological material
This image provided by United States District Court For The Eastern District Of Michigan shows toxic plant pathogens that a Chinese scientist entered the U.S. last year stashed in his backpack, federal authorities said Tuesday, June 3, 2025, as they filed charges against him and a girlfriend who worked in a lab at the University of Michigan. (United States District Court For The Eastern District Of Michigan via AP) A DETROIT — A Chinese scientist was arrested while arriving in the U.S. at the Detroit airport, the second case in days involving the alleged smuggling of biological material, authorities said Monday. The scientist is accused of shipping biological material months ago to staff at a laboratory at the University of Michigan. The FBI, in a court filing, described it as material related to certain worms and requires a government permit. 'The guidelines for importing biological materials into the U.S. for research purposes are stringent, but clear, and actions like this undermine the legitimate work of other visiting scholars,' said John Nowak, who leads field operations at U.S. Customs and Border Protection. The scientist was interviewed and arrested Sunday after arriving on a flight from China, where she is pursuing an advanced degree at Huazhong University of Science and Technology in Wuhan. She planned to spend a year completing a project at the University of Michigan. Her shipments, including an envelope stuffed inside a book, were intercepted last year and earlier this year and opened by authorities, the FBI said. The court filing doesn't indicate whether the FBI believes the biological material was dangerous, though U.S. Attorney Jerome Gorgon Jr. said smuggling 'threatens our security.' The government last week charged two Chinese scientists who are accused of conspiring to smuggle a toxic fungus into the U.S. One was turned around at the Detroit airport and sent back to China last year, while the other, a researcher at the University of Michigan, was arrested. She remains in custody. Ed White, The Associated Press
Globe and Mail
3 hours ago
- Globe and Mail
IonQ Pops on Nvidia Collab. How Should You Play the Quantum Computing Stock Here?
IonQ (IONQ) shares are inching up at writing after the quantum technology specialist announced successful results from a high-profile research collaboration with Nvidia (NVDA), Amazon (AMZN) and AstraZeneca (AZN). On Monday, the group demonstrated quantum-accelerated computational chemistry workflow that could dramatically reduce the time required for drug development. Including today's gain, IONQ stock is up 120% versus its year-to-date low in March. Significance of Nvidia Collaboration for IonQ Stock The aforementioned collaboration is meaningful for IonQ shares as it validates the company's hybrid quantum-classical computing model in a real-world, high-stakes application: drug discovery. By linking its quantum hardware with Nvidia's advanced GPU acceleration and AWS' scalable infrastructure, the NYSE-listed firm has demonstrated tangible value in a notoriously computation-heavy sector. Not only do the findings strengthen IonQ's commercial credibility, but they also position it as a key player in the fast-emerging market of quantum-enhanced molecular modeling. Simply put, the research could open doors for more enterprise partnerships and significant revenue opportunities, which may translate to an increase in this quantum computing stock's price over time. IONQ Shares Gain on Oxford Ionics Acquisition IonQ shares are trending up at the time of writing also because the NYSE-listed firm announced a $1.1 billion acquisition of Oxford Ionics on Monday. Bringing the UK-based startup, known for its innovative trapped-ion quantum computing systems, under its umbrella strengthens IONQ's technology portfolio and global presence. The deal could accelerate IonQ's roadmap by integrating Oxford's breakthroughs with its hardware and cloud infrastructure. It also positions the company as a more formidable player in the race for commercial quantum advantage, expanding its tale base and IP. Still, analysts recommend caution in buying IONQ stock at current levels. Is It Too Late to Invest in IonQ? According to Wall Street analysts, a massive rally in IonQ shares over the past three months has baked in a lot of the good news already. While the consensus rating on IONQ still currently sits at ' Moderate Buy,' the mean target of $40 suggests the quantum computing stock is fairly valued and lacks any further upside from here.
Globe and Mail
5 hours ago
- Globe and Mail
Acquisitions, Licensing Deals Take Centerstage in Pharma/Biotech Space
Mergers and Acquisitions (M&A) have picked up significant pace in 2025 in the pharma/biotech sector after a passive run in 2024. The recent spree of acquisitions signifies a focus on portfolio expansion and constant pipeline innovation, given the changing landscape and spotlight on AI-driven drug discovery. Simultaneously, bigwigs in the space also enter into licensing deals and collaborations for a promising drug/candidate to strengthen and expand their portfolios in their respective core areas. Quick Take on Recent Acquisitions & Deals Pharma giant Sanofi SNY recently announced that it will acquire Blueprint Medicines for a total deal value of up to $9.5 billion to expand its portfolio in rare immunological disease and add an early-stage pipeline in immunology. The impending acquisition will add Blueprint Medicines' only marketed product, Ayvakit (avapritinib), an inhibitor of KIT and PDGFRA proteins, to Sanofi's commercial portfolio. Bristol Myers Squibb BMY recently announced a strategic collaboration agreement with BioNTech for the global co-development and co-commercialization of the latter's investigational bispecific antibody BNT327 across numerous solid tumor types. BNT327, a next-generation bispecific antibody candidate, targets PD-L1 and VEGF-A. Per the terms, BMY will make an upfront payment of $1.5 billion to BioNTech. In addition, BioNTech will also receive $2 billion in non-contingent anniversary payments through 2028. Developing bispecific antibodies that target two proteins, namely PD-1 and VEGF, has lately been one of the lucrative areas in cancer treatment, attracting other pharma giants as well. In May 2025, Pfizer inked a licensing agreement with 3SBio for the development, manufacturing and commercialization of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, outside China. While oncology and immuno-oncology companies have always been at the top of acquisition targets, the lucrative obesity sector and gene-editing space are also being eyed. Last week, Regeneron REGN entered into an in-licensing agreement for an obesity drug with Hansoh Pharmaceuticals Group Company Limited, in a bid to expand its clinical-stage obesity portfolio. The licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist. M&A in Focus in 2025 Consolidation has long been a central focus in the pharma/biotech industry. This is because leading companies constantly look to diversify their revenue base in the face of dwindling sales of their high-profile drugs. Acquisitions also make sense as developing a drug/technology from scratch is costly and risky. In April, pharma giant Johnson & Johnson acquired Intra-Cellular Therapies for approximately $14.6 billion and added antidepressant drug, Caplyta, to its neuroscience portfolio. Swiss pharma bigwig Novartis NVS, too, has been on an acquisition spree. Novartis is all set to acquire San Diego-based clinical-stage biopharmaceutical company Regulus Therapeutics to strengthen its renal disease portfolio. Regulus' lead asset, farabursen, is a potential first-in-class, next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease. In April, Germany-based Merck KGaA announced that it will acquire SpringWorks Therapeutics, Inc. for $3.9 billion to expand business in the United States. SpringWorks Therapeutics, a U.S.-based biopharma company, has a portfolio that comprises a first-in-class, systemic standard-of-care therapy in adults with desmoid tumors and the first and only approved therapy for adults and children with neurofibromatosis type 1-associated plexiform neurofibromas. Potential Deals We expect M&A activity to accelerate further in 2025, given the massive cash reserve owned by major pharma and biotech companies. These companies will also look to utilize innovative technology to develop breakthrough treatments rapidly as the landscape evolves. Moreover, smaller biotechs often lack the necessary funds to successfully develop a drug and commercialize thereafter. The recent spotlight on the usage of AI technology for drug discovery should lure investment in this industry. Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Sanofi (SNY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Bristol Myers Squibb Company (BMY): Free Stock Analysis Report
